| P2093 | author name string | Esther Lutgens | |
| | Lena Bosch | |
| | Laura A Bosmans | |
| | Tom T P Seijkens | |
| | Pascal J H Kusters | |
| P2860 | cites work | The SNP rs1883832 in CD40 gene and risk of atherosclerosis in Chinese population: a meta-analysis | Q33610203 |
| | Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome | Q33646945 |
| | Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile | Q33656103 |
| | CD40L and Its Receptors in Atherothrombosis-An Update | Q33814059 |
| | Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. | Q33912722 |
| | Association between levels of circulating soluble CD40 ligand on admission and in-hospital events among acute coronary syndrome patients | Q33969881 |
| | Soluble CD40 ligand stimulates the pro-angiogenic function of peripheral blood angiogenic outgrowth cells via increased release of matrix metalloproteinase-9. | Q35073314 |
| | Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice | Q35160907 |
| | Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype | Q35161070 |
| | Discovery of small molecule CD40-TRAF6 inhibitors | Q35549406 |
| | Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography | Q35633740 |
| | Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice | Q35795164 |
| | Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis | Q36028683 |
| | Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. | Q36344730 |
| | Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling | Q36350146 |
| | Systemic blood coagulation activation in acute coronary syndromes | Q37116951 |
| | The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. | Q37555464 |
| | Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance | Q37599837 |
| | Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome | Q38220415 |
| | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 |
| | Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis | Q38892849 |
| | Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis | Q39215639 |
| | Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. | Q40049103 |
| | CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation. | Q40256254 |
| | CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines | Q40761122 |
| | TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. | Q42509065 |
| | Crosstalk between T cells and bronchial fibroblasts obtained from asthmatic subjects involves CD40L/alpha 5 beta 1 interaction | Q43062632 |
| | Exploring immune checkpoints as potential therapeutic targets in atherosclerosis | Q47224948 |
| | The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling | Q47245105 |
| | Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis | Q47993155 |
| | A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense | Q48095930 |
| | A comparative study of biomarkers for risk prediction in acute coronary syndrome-Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. | Q48133497 |
| | Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation | Q48431300 |
| | Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. | Q49369729 |
| | Distinct CD40L receptors mediate inflammasome activation and secretion of IL-1β and MCP-1 in cultured human retinal pigment epithelial cells. | Q49895966 |
| | Relation of C4b-binding protein to athero-sclerosis of the descending thoracic aorta. | Q51583432 |
| | CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. | Q51798890 |
| | Requirement for CD154 in the progression of atherosclerosis. | Q52536870 |
| | Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells. | Q52973871 |
| | Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes. | Q53192004 |
| | The CD40 gene polymorphism rs1883832 is associated with risk of acute coronary syndrome in a Chinese case-control study. | Q54401140 |
| | Multiple effects of CD40–CD40L axis in immunity against infection and cancer. | Q55518078 |
| | Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma | Q57313116 |
| | Soluble CD40 Ligand in Acute Coronary Syndromes | Q58816350 |
| | Complement regulation in human atherosclerotic coronary lesions | Q59244329 |
| | C4b-Binding Protein (C4BP) Activates B Cells through the CD40 Receptor | Q60250685 |
| | CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism | Q63354517 |
| | Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates | Q63560435 |
| | Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease | Q64087475 |
| | Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction. | Q64894351 |
| | Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes | Q74121901 |
| | Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 | Q81400150 |
| | HSP 70 and atherosclerosis--protector or activator? | Q83390162 |
| | The role of CD154 in haematopoietic development | Q84699936 |
| | Soluble CD40 ligand impairs the anti-platelet function of peripheral blood angiogenic outgrowth cells via increased production of reactive oxygen species | Q86174278 |
| | Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction | Q87367180 |
| | Influence of circadian blood pressure alterations on serum SCUBE-1 and soluble CD40 ligand levels in patients with essential hypertension | Q90088047 |
| | Association of soluble CD40L with short-term and long-term cardiovascular and all-cause mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study | Q90314267 |
| | Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond | Q90539200 |
| | Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure | Q90908612 |
| | Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events | Q91071188 |
| | Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction | Q91304576 |
| | Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort | Q92037032 |
| | Low-Dose Methotrexate for the Prevention of Atherosclerotic Events | Q92980641 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P577 | publication date | 2020-03-28 | |
| P1433 | published in | Journal of Cardiovascular Translational Research | Q6294906 |
| P1476 | title | The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease | |